Claudin (CLDN) Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
EGTA | 67-42-5 | sc-3593 sc-3593A sc-3593B sc-3593C sc-3593D | 1 g 10 g 100 g 250 g 1 kg | $20.00 $62.00 $116.00 $246.00 $799.00 | 23 | |
Calcium chelator, can disrupt calcium-dependent cell adhesion, potentially affecting Claudins. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $94.00 $286.00 | 27 | |
The Wnt signaling pathway is involved in cell polarity and tight junction formation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
Modulates signaling pathways, can indirectly influence Claudins in cell-cell adhesion. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
ROCK inhibitor, affects cytoskeletal organization, potentially impacting Claudin function. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $107.00 $224.00 | 9 | |
Bumetanide, a loop diuretic, indirectly influences Claudins by targeting the Na+-K+-2Cl- cotransporter (NKCC2). NKCC2 is involved in ion transport and tight junction regulation. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
ML-7, a myosin light chain kinase (MLCK) inhibitor, indirectly influences Claudins by disrupting the MLCK signaling pathway. MLCK is involved in actin cytoskeleton remodeling and tight junction regulation. | ||||||
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $26.00 $77.00 $151.00 $303.00 | 1 | |
Flufenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), indirectly modulates Claudins by targeting the calcium-sensing receptor (CaSR) signaling pathway. CaSR is involved in ion transport and tight junction regulation. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $110.00 $440.00 $660.00 $1200.00 | 2 | |
ML-9, a selective myosin light chain kinase (MLCK) inhibitor, indirectly influences Claudins by disrupting the MLCK signaling pathway. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $92.00 $182.00 | 71 | |
H-89, a protein kinase A (PKA) inhibitor, indirectly modulates Claudins by disrupting the PKA signaling pathway. PKA is involved in tight junction regulation. Inhibition of PKA by H-89 alters the dynamic regulation of Claudins, impacting its localization and function within tight junctions. | ||||||